本文選題：乳腺癌 + 易感性��； 參考：《鄭州大學(xué)》2017年碩士論文

【摘要】：乳腺癌是女性最常見的癌癥。在中國(guó)乳腺癌還是引起中國(guó)女性癌癥死亡的首要病因。流行病學(xué)研究表明乳腺癌的發(fā)生發(fā)展通常是由遺傳、環(huán)境、生活方式和生殖危險(xiǎn)因素的相互作用引起的。全基因組關(guān)聯(lián)研究(Genome Wide Association Study,GWAS)顯示在HRR通路上的DNA修復(fù)基因如RAD51、RAD52、XRCC2、BRCA1和BRCA2會(huì)導(dǎo)致乳腺癌的發(fā)生。在這些基因3’非編碼區(qū)(3’UTR)的單核苷酸多態(tài)性可以通過擾亂現(xiàn)有的或創(chuàng)造miRNAs的結(jié)合位點(diǎn)來調(diào)控基因的表達(dá)水平,進(jìn)而導(dǎo)致疾病的發(fā)生。還有研究表明Linc-ROR在癌癥包括乳腺癌的發(fā)展中起著重要的作用。然而可以調(diào)節(jié)這些基因表達(dá)水平的潛在功能性單核苷酸多態(tài)性(SNP)還未被大量研究。目的本研究的目的是評(píng)估十一個(gè)SNPs和乳腺癌的遺傳易感性之間的相關(guān)性以及十一個(gè)SNPs與生殖因素之間的交互作用。此外,對(duì)于篩選出與乳腺癌有關(guān)聯(lián)性的SNP對(duì)應(yīng)的miRNA和Linc-ROR的標(biāo)簽SNP進(jìn)行進(jìn)一步的功能驗(yàn)證,從而探索miRNA調(diào)控乳腺癌發(fā)生的機(jī)制。方法(1)結(jié)合NCBI dbSNP數(shù)據(jù)庫(kù)、查閱國(guó)內(nèi)外相關(guān)文獻(xiàn)、預(yù)測(cè)miRNA結(jié)合位點(diǎn)的相關(guān)軟件以及篩選標(biāo)簽SNP的heploview軟件,利用生物信息學(xué)方法篩選了HRR通路選定基因(BRCA1、BRCA2、RAD51、RAD52和XRCC2)的miRNA靶序列SNPs(rs8176318、rs12516、rs15869、rs7180135、rs45549040、rs1051669、rs3218550)以及Linc-ROR的標(biāo)簽SNPs(rs1942348、rs4801078、rs6420545和rs9636089);(2)在本次病例對(duì)照研究中,根據(jù)研究功效(0.9)和最小等位基因頻率(0.25),利用PASS軟件計(jì)算樣本量為n=459。本研究納入了來自河南省的498例乳腺癌患者和按年齡(±2歲)與之進(jìn)行頻數(shù)匹配的健康對(duì)照者498例。采用限制片段多態(tài)性(PCR-RFLP)和等位基因特異性(AS-PCR)的方法對(duì)研究對(duì)象的DNA樣本進(jìn)行基因分型。分型結(jié)果首先進(jìn)行Hardy-weinberg平衡的檢驗(yàn)以保證對(duì)照人群的代表性。采用非條件logistic回歸模型分析不同基因型與乳腺癌發(fā)病風(fēng)險(xiǎn)的關(guān)聯(lián),并進(jìn)一步使用多因子降維的方法分析基因與環(huán)境的交互作用。此外SHEsis在線軟件用作基因BRCA1和Linc-ROR的單體型分析。(3)miRNA-627的過表達(dá)載體與miRNA-627抑制劑分別轉(zhuǎn)染到乳腺癌細(xì)胞系MDA-MB-231與MCF-7中,利用qRT-PCR的方法來檢測(cè)不同組內(nèi)細(xì)胞miRNA-627與mRNA BRCA2的相對(duì)表達(dá)量;采用qRT-PCR的方法檢測(cè)不同基因型樣本的血漿Linc-ROR的表達(dá)水平,從而研究Linc-ROR的單核苷酸多態(tài)性對(duì)自身表達(dá)水平的影響。結(jié)果(1)BRCA1 rs8176318 GT(OR:1.332;95%CI:1.007-1.761)與GT+TT(OR:1.336;95%CI:1.018-1.753)基因型可以增加乳腺癌的發(fā)病風(fēng)險(xiǎn);此外,BRCA1基因Crs8176318Trs12516的單體型在對(duì)照組中的頻率明顯高于病例組,而BRCA1基因Trs8176318Trs12516的單體型在對(duì)照組中的頻率顯著低于病例組。(2)BRCA2 rs15869 AC(OR:1.524;95%CI:1.141-2.035)基因型也可以增加乳腺癌的發(fā)病風(fēng)險(xiǎn),分層分析顯示rs15869 AC+CC基因型在年齡大于50歲(OR:1.486,95%CI:1.047-2.109)、月經(jīng)初潮年齡≤13歲(OR:1.53,95%CI:1.07-2.188)、絕經(jīng)年齡50歲(OR:2.185,95%CI:1.094-4.366)、絕經(jīng)前(OR:1.344,95%CI:1.022-1.767)、妊娠≤2次(OR:1.639,95%CI:1.189-2.261)、流產(chǎn)≤2次(OR:1.392,95%CI:1.1-1.762)、母乳喂養(yǎng)(OR:3.576,95%CI:1.35-9.475)和無前一級(jí)親屬腫瘤家族史(OR:1.347,95%CI:1.08-1.679)的人群中增加乳腺癌的發(fā)病風(fēng)險(xiǎn)。(3)RAD51/RAD52/XRCC2 RAD51基因rs45549040 AC+CC基因型在妊娠數(shù)2次的女性人群中可以降低乳腺癌的發(fā)病風(fēng)險(xiǎn)(OR:0.631,95%CI:0.406-0.98);RAD52基因rs1051669 GA+AA基因型可以增加絕經(jīng)前女性的乳腺癌風(fēng)險(xiǎn)(OR:1.519,95%CI:1.076-2.146);XRCC2 rs3218550 GA+AA基因型在年齡小于50歲(OR:0.627,95%CI:0444-0.885)和月經(jīng)初潮年齡≤13歲(OR:0.538,95%CI:0.330-0.874)的人群中降低了乳腺癌的風(fēng)險(xiǎn)。(4)Linc-ROR rs4801078 TT(OR:1.791;95%CI:1.195-2.683)可以增加乳腺癌的發(fā)病風(fēng)險(xiǎn);Linc-ROR單體型Trs6420545Crs4801078Trs1942348Trs9636089的頻率在對(duì)照組相對(duì)較高。(5)基因-生殖因素交互作用分析結(jié)果:攜帶rs15869位點(diǎn)C等位基因、初潮年齡≤13歲和懷孕次數(shù)≥2次的人群乳腺癌的發(fā)病風(fēng)險(xiǎn)是不具有這些危險(xiǎn)因素人群的2.39倍(OR:2.39;95%CI:1.04-5.47);rs4801078、懷孕次數(shù)以及絕經(jīng)狀態(tài)三者之間的交互作用可以提高乳腺的發(fā)病風(fēng)險(xiǎn)(OR:2.78;95%CI:2.74-3.61)。(6)實(shí)時(shí)定量PCR結(jié)果:成功轉(zhuǎn)染了pGenesil-1-miRNA-627過表達(dá)質(zhì)粒的乳腺癌細(xì)胞系中BRCA2的表達(dá)水平較轉(zhuǎn)染了空質(zhì)粒的對(duì)照組顯著降低(P0.05),而成功轉(zhuǎn)染miRNA-627抑制物的兩個(gè)乳腺癌細(xì)胞系BRCA2的相對(duì)表達(dá)水平較其對(duì)照組顯著增高(P0.05);Linc-ROR的表達(dá)水平在rs4801078 CT+TT基因型組的人群中(1.94±0.55)顯著高于CC基因型組的人群(1.21±0.49)。結(jié)論(1)BRCA1 rs8176318 GT/GT+TT與BRCA2 rs15869 AC基因型可以增加乳腺癌的發(fā)病風(fēng)險(xiǎn);(2)Linc-ROR rs4801078 TT基因型可以增加乳腺癌的發(fā)病風(fēng)險(xiǎn);(3)攜帶rs15869位點(diǎn)C等位基因、初潮年齡≤13歲和懷孕次數(shù)≥2次的人群乳腺癌的發(fā)病風(fēng)險(xiǎn)是不具有這些危險(xiǎn)因素人群的2.39倍,rs4801078、懷孕次數(shù)以及絕經(jīng)狀態(tài)三者之間的交互作用可以提高乳腺的發(fā)病風(fēng)險(xiǎn);(4)成功轉(zhuǎn)染的pGenesil-1-miRNA-627過表達(dá)質(zhì)粒在乳腺癌細(xì)胞系MCF-7與MDA-MB-231中成功上調(diào)了BRCA2的表達(dá)水平;rs4801078 CT+TT基因型與健康對(duì)照人群中血漿Linc-ROR的表達(dá)水平顯著相關(guān)。
[Abstract]:Breast cancer is the most common cancer in women. In China, breast cancer is the leading cause of cancer death in Chinese women. Epidemiological studies show that the development of breast cancer is usually caused by the interaction of genetic, environmental, lifestyle, and reproductive risk factors. Genome Wide Association Study, GWAS) The DNA repair genes on the HRR pathway such as RAD51, RAD52, XRCC2, BRCA1 and BRCA2 can lead to the occurrence of breast cancer. Single nucleotide polymorphisms in these 3 'non coding regions (3' UTR) can regulate the level of gene expression by disrupting existing or creating miRNAs binding sites, leading to the occurrence of the disease. Linc-ROR plays an important role in the development of cancer, including breast cancer. However, the potential functional single nucleotide polymorphisms (SNP), which can regulate these gene expressions, have not been extensively studied. The purpose of this study was to assess the correlation between the genetic susceptibility to eleven SNPs and breast cancer and eleven SNPs and reproductive causes. In addition, further functional validation of the miRNA and Linc-ROR label SNP corresponding to SNP, which is associated with breast cancer, is further explored to explore the mechanism of miRNA regulation of the occurrence of breast cancer. Method (1) combining the NCBI dbSNP database, consulting the relevant literature at home and abroad, and predicting the related software of the miRNA binding site. And screening the heploview software of the label SNP, using the Bioinformatics Method to screen the miRNA target sequences of the selected HRR pathway (BRCA1, BRCA2, RAD51, RAD52 and XRCC2). (2) In a case-control study, according to the study efficacy (0.9) and the minimum allele frequency (0.25), 498 cases of breast cancer from Henan province and 498 healthy controls who were matched by age (2 years old) were included in the PASS software n=459.. Limited fragment polymorphism (PCR-RFLP) and alleles were used. The specific (AS-PCR) method was used to genotyping the DNA samples of the subjects. The results of the typing were first tested to ensure the representation of the control population. A non conditional logistic regression model was used to analyze the association between the different genotypes and the risk of breast cancer, and the method of multi factor reduction was further used. The interaction between gene and environment. In addition, SHEsis online software is used as a haplotype analysis of gene BRCA1 and Linc-ROR. (3) the overexpression vector of miRNA-627 and miRNA-627 inhibitors are transfected into breast cancer cell line MDA-MB-231 and MCF-7 respectively. The relative expression of miRNA-627 and mRNA BRCA2 in different groups of cells is detected by qRT-PCR method. The qRT-PCR method was used to detect the expression level of plasma Linc-ROR in different genotype samples, and the effect of single nucleotide polymorphism of Linc-ROR on the level of self expression was investigated. Results (1) the genotype of BRCA1 rs8176318 GT (OR:1.332; 95%CI:1.007-1.761) and GT+TT (OR:1.336; 95%CI: 1.018-1.753) could increase the risk of breast cancer. In addition, the frequency of haplotype of BRCA1 gene Crs8176318Trs12516 was significantly higher in the control group than in the case group, while the frequency of the haplotype of BRCA1 gene Trs8176318Trs12516 was significantly lower in the control group than in the case group. (2) the BRCA2 rs15869 AC (OR:1.524; 95%CI:1.141-2.035) genotype also increased the risk of breast cancer, and the stratified analysis showed rs15. 869 AC+CC genotype at age 50 (OR:1.486,95%CI:1.047-2.109), menarche age less than 13 years (OR:1.53,95%CI:1.07-2.188), menopause age 50 (OR:2.185,95%CI:1.094-4.366), Premenopause (OR:1.344,95%CI:1.022-1.767), pregnancy less than 2 times (OR:1.639,95%CI:1.189-2.261), abortion less than 2 times (OR:1.392,95%CI:1.1-1.762), breastfeeding ( OR:3.576,95%CI:1.35-9.475) and the risk of breast cancer (3) the rs45549040 AC+CC genotype of the RAD51/RAD52/XRCC2 RAD51 gene can reduce the risk of breast cancer (OR:0.631,95%CI:0.406-0.98) and RAD52 gene r in a group of women with 2 times of pregnancy. The s1051669 GA+AA genotype can increase the risk of breast cancer in premenopausal women (OR:1.519,95%CI:1.076-2.146); the XRCC2 rs3218550 GA+AA genotype reduces the risk of breast cancer in people younger than 50 years of age (OR:0.627,95%CI:0444-0.885) and menarche age less than 13 years (OR:0.538,95%CI:0.330-0.874). (4) Linc-ROR rs4801078 TT (OR:) (OR:) 1.791; 95%CI:1.195-2.683) can increase the risk of breast cancer; the frequency of Linc-ROR haplotype Trs6420545Crs4801078Trs1942348Trs9636089 is relatively high in the control group. (5) the interaction analysis of gene - reproductive factors: the C allele of the rs15869 locus, the onset of breast cancer in the population with the age of menarche less than 13 years and more than 2 times of pregnancy The risk of the disease was 2.39 times (OR:2.39; 95%CI:1.04-5.47) of those who did not have these risk factors; rs4801078, the number of pregnancies and the interplay between the three of the menopause could improve the risk of breast disease (OR:2.78; 95%CI:2.74-3.61). (6) the real-time quantitative PCR results: the successful transfection of the pGenesil-1-miRNA-627 overexpressed plasmid in the breast cancer The expression level of BRCA2 in the cell lines was significantly lower than that of the control group transfected with empty plasmids (P0.05), while the relative expression level of BRCA2 in two breast cancer cell lines successfully transfected with miRNA-627 inhibitor was significantly higher than that of the control group (P0.05), and the expression level of Linc-ROR was significantly higher than the CC base in the rs4801078 CT+ TT genotype group (1.94 + 0.55). The population of the type group (1.21 + 0.49). Conclusion (1) BRCA1 rs8176318 GT/GT+TT and BRCA2 rs15869 AC genotype can increase the risk of breast cancer; (2) the Linc-ROR rs4801078 TT genotype can increase the risk of breast cancer; (3) carry the C allele of the rs15869 locus, the age of the menarche less than 13 years and the number of pregnancies more than 2 times in the population of breast cancer The risk of the disease is 2.39 times as high as those of the people who do not have these risk factors. Rs4801078, the number of pregnancies and the interaction between the three of the menopause state can increase the risk of breast disease. (4) the successful transfected pGenesil-1-miRNA-627 overexpressed plasmid successfully up-regulated the expression level of BRCA2 in the breast cancer cell line MCF-7 and MDA-MB-231; rs480107 8 the genotype of CT+TT was significantly correlated with the level of plasma Linc-ROR in healthy controls.
【學(xué)位授予單位】：鄭州大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 ;鈣粘素E水平低提示乳腺癌細(xì)胞轉(zhuǎn)移[J];中國(guó)腫瘤;2000年08期

2 黃嘯原;用“印度閱兵”形容乳腺癌合適嗎?[J];診斷病理學(xué)雜志;2001年02期

3 張嘉慶,王殊,喬新民;乳腺癌的現(xiàn)狀和遠(yuǎn)景[J];中華外科雜志;2002年03期

4 張維彬,汪波,石靈春;中醫(yī)藥在現(xiàn)代乳腺癌治療中的運(yùn)用[J];中國(guó)中西醫(yī)結(jié)合急救雜志;2002年01期

5 薛志勇;食物與乳腺癌[J];山東食品科技;2002年04期

6 王旬果,王建軍,鄭國(guó)華;乳腺癌相關(guān)標(biāo)志物的研究進(jìn)展[J];山東醫(yī)藥;2002年33期

7 陸尚聞;;男人也患乳腺癌[J];環(huán)境;2003年12期

8 ;新技術(shù)清晰拍攝早期乳腺癌細(xì)胞[J];上海生物醫(yī)學(xué)工程;2005年04期

9 田富國(guó);郭向陽;張華一;;乳腺癌診治研究新進(jìn)展[J];腫瘤研究與臨床;2005年S1期

10 馬濤,谷俊朝;血管內(nèi)皮生長(zhǎng)因子與乳腺癌的臨床研究進(jìn)展[J];國(guó)外醫(yī)學(xué)(外科學(xué)分冊(cè));2005年01期

相關(guān)會(huì)議論文 前10條

1 于永利;;抗乳腺癌免疫治療融合蛋白[A];中國(guó)免疫學(xué)會(huì)第四屆學(xué)術(shù)大會(huì)會(huì)議議程及論文摘要集[C];2002年

2 郭紅飛;;中醫(yī)治療乳腺癌的策略[A];江西省中醫(yī)、中西醫(yī)結(jié)合腫瘤學(xué)術(shù)交流會(huì)論文集[C];2012年

3 龐朋沙;伍會(huì)健;;乳腺癌治療靶標(biāo)的研究進(jìn)展[A];北方遺傳資源的保護(hù)與利用研討會(huì)論文匯編[C];2010年

4 陸勁松;邵志敏;吳炅;韓企夏;沈鎮(zhèn)宙;;新型維甲酸抑制乳腺癌細(xì)胞的生長(zhǎng)及誘導(dǎo)凋亡的機(jī)制研究[A];2000全國(guó)腫瘤學(xué)術(shù)大會(huì)論文集[C];2000年

5 劉愛國(guó);胡冰;;乳腺癌臨床治療進(jìn)展[A];安徽省抗癌協(xié)會(huì)第四次代表大會(huì)暨乳腺癌、肺癌專業(yè)委員會(huì)成立會(huì)議、安徽省腫瘤防治進(jìn)展學(xué)術(shù)研討會(huì)論文匯編[C];2001年

6 張嘉慶;王殊;喬新民;;乳腺癌的現(xiàn)狀和遠(yuǎn)景[A];第一屆全國(guó)中西醫(yī)結(jié)合乳腺疾病學(xué)術(shù)會(huì)議論文匯編[C];2002年

7 劉清俊;;乳腺癌綜合治療的新進(jìn)展[A];山西省抗癌協(xié)會(huì)第六屆腫瘤學(xué)術(shù)交流會(huì)論文匯編[C];2003年

8 邵志敏;;21世紀(jì)乳腺癌治療的展望[A];第三屆中國(guó)腫瘤學(xué)術(shù)大會(huì)教育論文集[C];2004年

9 陳松旺;張明;;乳腺癌治療的回顧與展望[A];西部地區(qū)腫瘤學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2004年

10 白霞;傅建新;丁凱陽;王兆鉞;阮長(zhǎng)耿;;組織因子途徑抑制物-2在乳腺癌細(xì)胞中的表達(dá)研究[A];第10屆全國(guó)實(shí)驗(yàn)血液學(xué)會(huì)議論文摘要匯編[C];2005年

相關(guān)重要報(bào)紙文章 前10條

1 ;血檢有望揭示乳腺癌治療效果[N];醫(yī)藥經(jīng)濟(jì)報(bào);2004年

2 記者 鄭曉春;乳腺癌細(xì)胞擴(kuò)散基因被找到[N];科技日?qǐng)?bào);2007年

3 中國(guó)軍事醫(yī)學(xué)科學(xué)院腫瘤中心主任 宋三泰;乳腺癌有了新療法[N];中國(guó)婦女報(bào);2002年

4 王艷紅;抑制ＤＮＡ修補(bǔ)可消滅乳腺癌細(xì)胞[N];醫(yī)藥經(jīng)濟(jì)報(bào);2005年

5 詹建;乳腺癌飲食 兩個(gè)時(shí)期不一樣[N];中國(guó)中醫(yī)藥報(bào);2006年

6 辛君;乳腺癌擴(kuò)散基因“浮出水面”[N];大眾衛(wèi)生報(bào);2009年

7 記者 毛黎;美發(fā)現(xiàn)有效抑制乳腺癌細(xì)胞生長(zhǎng)的分子[N];科技日?qǐng)?bào);2010年

8 記者 吳春燕　通訊員 王麗霞;乳腺癌治療將有新途徑[N];光明日?qǐng)?bào);2011年

9 王樂　沈基飛;我科學(xué)家發(fā)現(xiàn)導(dǎo)致乳腺癌耐藥的新標(biāo)志物[N];科技日?qǐng)?bào);2011年

10 劉霞;一種天然分子能阻止乳腺癌惡化[N];科技日?qǐng)?bào);2011年

相關(guān)博士學(xué)位論文 前10條

1 柴紅燕;疾病狀態(tài)下CYP4Z1和4A的生物學(xué)行為及其藥物干預(yù)研究[D];武漢大學(xué);2012年

2 李凱;ID(inhibitor of DNA binding)家族蛋白調(diào)控乳腺細(xì)胞的分化并影響乳腺癌的預(yù)后[D];復(fù)旦大學(xué);2014年

3 江一舟;乳腺癌新輔助化療前后基因變異檢測(cè)及其功能論證[D];復(fù)旦大學(xué);2014年

4 馬邵;酪氨酸去磷酸化增強(qiáng)表皮生長(zhǎng)因子受體在乳腺癌治療中靶向性的研究[D];山東大學(xué);2015年

5 姚若斯;精氨酸甲基轉(zhuǎn)移酶PRMT7誘導(dǎo)乳腺癌細(xì)胞發(fā)生表皮—間質(zhì)轉(zhuǎn)換及轉(zhuǎn)移的作用機(jī)制研究[D];東北師范大學(xué);2015年

6 侯培鋒;α-酮戊二酸二甲酯(DM-2KG)上調(diào)缺氧誘導(dǎo)因子-1α(HIF-1α)誘發(fā)高致瘤性干細(xì)胞樣乳腺癌細(xì)胞機(jī)制研究[D];福建醫(yī)科大學(xué);2014年

7 李麗麗;分泌蛋白SHON調(diào)控乳腺癌細(xì)胞EMT的分子機(jī)制研究[D];東北師范大學(xué);2015年

8 陳麗艷;PI3K抑制劑聯(lián)合組蛋白去乙酰化酶抑制劑對(duì)乳腺癌協(xié)同殺傷作用的分子機(jī)制研究[D];延邊大學(xué);2015年

9 樸俊杰;乳腺癌差異基因篩選及PAIP1對(duì)其生物學(xué)行為的影響[D];延邊大學(xué);2015年

10 汪[?如;染色體6q25.1區(qū)域基因多態(tài)性與乳腺癌遺傳易感性的關(guān)聯(lián)研究[D];南方醫(yī)科大學(xué);2015年

相關(guān)碩士學(xué)位論文 前10條

1 杜文英;乳腺癌分子亞型的臨床與病理特點(diǎn)[D];鄭州大學(xué);2011年

2 賈曉菲;彩色多普勒超聲與乳腺癌病理及免疫組化指標(biāo)的相關(guān)性研究[D];內(nèi)蒙古大學(xué);2015年

3 靳文;乳腺癌全基因組DNA甲基化修飾的研究[D];內(nèi)蒙古大學(xué);2015年

4 吳坤琳;TLR4/MyD88信號(hào)通路對(duì)乳腺癌侵襲性影響的實(shí)驗(yàn)研究[D];福建醫(yī)科大學(xué);2015年

5 葛廣哲;樹，

本文編號(hào)：1956708